Last reviewed · How we verify
NCT04766502: PIPADN
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
NA trial testing Blood sample (20 ml) and EORTC QLQC30 survey in Peritoneal Carcinomatosis in 20 participants. Completed in 7 January 2025.
10 December 2024
Quick facts
| Lead sponsor | Institut de Cancérologie de Lorraine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 11 January 2022 |
| Primary completion | 10 December 2024 |
| Estimated completion | 7 January 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood sample (20 ml) and EORTC QLQC30 survey
Conditions studied
- Peritoneal Carcinomatosis — all drugs for Peritoneal Carcinomatosis →
Sponsor
Institut de Cancérologie de Lorraine — full company profile →
Who can join
18 and older, any sex, with Peritoneal Carcinomatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PIPADN is a pilot monocentric, study with a total duration of 42 months. The purpose of this study is to describe the variation of plasma ctDNA concentration between the 1st and the 3rd PIPAC session in patients with peritoneal carcinomatosis. The improvement of life quality with this type of treatment will also be evaluated though the EORTC QLQ-C30 survey. Each patient will have three PIPAC sessions spaced 6 to 8 weeks apart. Two blood samples will be taken during the first 3 PIPAC sessions, one the day before each procedure and a second one 24 hours afterwards. The EORTC QLQ 30 survey will be completed by patients during the pre-operative consultation and at each post-operative consultation (about 3 weeks after PIPAC sessions).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04766502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peritoneal Carcinomatosis
Currently open trials in the same condition.
- NCT04107077 — Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advance · Phase 2 · recruiting
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06929013 — Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer. · NA · recruiting
- NCT07514494 — Intensification Treatment of Ovarian Cancer by PIPAC · Phase 2 · recruiting
- NCT07493876 — Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With · NA · recruiting
Other Institut de Cancérologie de Lorraine trials
Trials by the same sponsor.
- NCT07326800 — Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cance · NA · recruiting
- NCT07089485 — Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees · NA · not yet recruiting
- NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
- NCT06884332 — Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality · NA · recruiting
- NCT06903104 — Acceptability and Feasibility of a Stress Prevention Program Based on Meditation and Acceptance and Commitment Therapy f · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766502 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Cancérologie de Lorraine
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing